Skye Bioscience, Inc. (SKYE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Skye Bioscience, Inc. is a clinical-stage biotechnology company developing next-generation molecules to treat obesity and related conditions. The company's lead candidate, nimacimab, is currently in a Phase 2a proof-of-concept clinical trial (CBeyond study). The company has not yet generated revenue and is focused on R&D, clinical trials, and capital raising.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(17.62) million | $(28.73) million | $(12.92) million |
| Operating Expenses | $18.24 million | $30.00 million | $14.56 million |
| R&D Expenses | $14.34 million | $21.54 million | $6.03 million |
| Cash & Equivalents | $23.84 million | $23.84 million | $68.42 million (Dec 31, 2024) |
| Short-term Investments | $24.75 million | $24.75 million | $0 |
| Total Liquidity | $48.59 million | $48.59 million | $68.42 million |
| Working Capital | $42.27 million | $42.27 million | $66.49 million |
| Accumulated Deficit | $(159.68) million | $(159.68) million | $(130.95) million |
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses surged 252% in Q2 and 257% YTD compared to 2024. This was driven by increased clinical trial costs for the nimacimab Phase 2a study and significant contract manufacturing costs ($6.6M increase in Q2) to resupply the extended study and prepare for Phase 2b.
- Cash Position: Cash and cash equivalents decreased from $68.4 million at year-end 2024 to $23.8 million at June 30, 2025. However, the company deployed $24.7 million into short-term investments, maintaining total liquidity of approximately $48.6 million.
- Legal Contingency: The estimated liability for the Wendy Cunning vs. Skye Bioscience litigation remains at $1.81 million. The case was remanded for a new trial in September 2025 after a favorable appellate ruling in late 2024.
- Debt Reduction: Interest expense dropped to zero in 2025 compared to $450k in Q2 2024, following the conversion of a $5 million secured promissory note into common stock in August 2024.
Guidance, Outlook, and Risks
- Clinical Outlook: The company anticipates a top-line readout from the CBeyond Phase 2a study in late Q3 or early Q4 2025. An extension study is underway to gather 52 weeks of treatment data.
- Liquidity Runway: Management believes current cash resources are sufficient to fund operations for at least 12 months from the filing date. However, future capital requirements depend on clinical results, and the company may need to seek additional funding sooner than planned.
- Capital Resources: The company has an At-The-Market (ATM) equity distribution agreement allowing for the sale of up to $100 million in stock, though no shares have been sold under this agreement to date.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the potential for increased legal costs related to the pending retrial, and the need for future financing to support Phase 2b studies and commercialization.
Investor Verification Checklist
- Verify the timeline and specific endpoints for the CBeyond Phase 2a top-line data readout expected in late 2025.
- Monitor the status of the Wendy Cunning litigation retrial scheduled for September 2025 and any updates to the $1.81 million legal accrual.
- Assess the company's cash burn rate relative to the $48.6 million liquidity position to confirm the 12-month runway estimate.
- Review the contract manufacturing costs ($9.1M increase YTD) to ensure alignment with the scale of the Phase 2b preparation.
- Check for any utilization of the $100 million ATM facility in upcoming filings.